BlackRock Technology and Private Equity Term Trust (BTX) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
P/E 2.32 means the share price is 2.32 times one year of earnings per share. Beta 1.27: the stock has moved about 27% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBlackRock Technology and Private Equity Term Trust (BTX) trades at $8.51. BlackRock Technology and Private Equity Term Trust is a non-diversified, closed-end management investment company. Sector: Healthcare.
Price as of · Last analyzed: May 10, 2026Analyst Coverage for BTX: BTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
BlackRock Technology and Private Equity Term Trust (BTX) Healthcare & Pipeline Overview
BlackRock Technology and Private Equity Term Trust (BTX) is a closed-end fund specializing in innovative mid- and small-cap growth companies within the technology and private equity sectors. With a focus on total return and income, BTX offers investors exposure to potentially high-growth ventures, reflected in its high profit margin and substantial dividend yield.
What Is the Investment Thesis for BTX?
BlackRock Technology and Private Equity Term Trust (BTX) presents an investment opportunity centered on its focus on innovative mid- and small-cap growth companies. With a high dividend yield of 9.42% and a profit margin of 87.7%, BTX offers a compelling income stream and potential for capital appreciation. The fund's strategy of targeting companies introducing disruptive products or services positions it to benefit from emerging market trends. However, investors may want to evaluate the risks associated with investing in non-diversified, closed-end funds, including market volatility and the potential for NAV fluctuations. The fund's beta of 1.27 indicates higher volatility compared to the broader market. The success of BTX hinges on its ability to identify and capitalize on innovative companies with sustainable growth prospects.
Based on FMP financials and quantitative analysis
BTX Key Highlights
Market Cap of $0.86B indicates a substantial investment pool focused on mid- and small-cap companies.
- P/E Ratio of 2.32 reflects investor expectations for future earnings growth from its portfolio companies.
- Profit Margin of 87.7% demonstrates the potential profitability of the companies held within the trust.
- Gross Margin of 100.0% suggests efficient revenue generation from its investments.
- Dividend Yield of 9.42% provides a significant income component for investors, supported by the trust's investment strategy.
Who Are BTX's Competitors?
BTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $39.13 | +0.20% | $173B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $517.49 | -1.23% | $131B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $807.67 | +0.33% | $83.2B | 95 5-pillar |
| ARGX argenx SE | $869.33 | -0.50% | $54.7B | 97 5-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $231.49 | +3.33% | $31.0B | 91 5-pillar |
| RPRX Royalty Pharma plc | $63.86 | +0.17% | $28.4B | 75 5-pillar |
| GMAB Genmab A/S | $43.79 | +9.47% | $26.9B | 62 5-pillar |
| UTHR United Therapeutics Corporation | $587.46 | -0.01% | $25.2B | 98 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BTX's Key Strengths?
Focus on innovative growth companies.
- High dividend yield of 9.42%.
- Strong profit margin of 87.7%.
- Access to BlackRock's resources and expertise.
What Are BTX's Weaknesses?
Non-diversified investment approach.
- High P/E ratio of 2.32.
- Beta of 1.27 indicates higher volatility.
- Newly organized with no operating history.
What Are the Key Risks for BTX?
Market volatility and economic downturns.
- Regulatory changes and healthcare reforms.
- Competition from other investment firms.
- Technological obsolescence and disruption.
- Risks associated with investing in non-diversified, closed-end funds.
What Are BTX's Competitive Advantages?
- Access to BlackRock's extensive research and investment resources.
- Focus on innovative mid- and small-cap companies with high growth potential.
- Closed-end fund structure provides a stable capital base for long-term investments.
- Experienced management team with a proven track record in growth investing.
What Does BTX Do?
BlackRock Innovation and Growth Trust (BTX) is a non-diversified, closed-end management investment company designed to provide investors with total return and income. The Trust achieves this objective through a combination of current income, current gains, and long-term capital appreciation. BTX strategically invests primarily in equity securities issued by mid- and small-capitalization companies, targeting those that the Trust's advisor believes possess above-average earnings growth potential. The Trust was newly organized and has no operating history. BTX's investment strategy centers around identifying and investing in innovative growth companies. These are defined as companies that have introduced, or are seeking to introduce, a new product or service with the potential to significantly alter the marketplace. By focusing on these types of companies, BTX aims to capture the upside potential of disruptive technologies and emerging market trends. The Trust's investment decisions are guided by the expertise of its advisor, who conducts thorough research and analysis to identify promising investment opportunities. The Trust operates primarily within the United States, focusing on companies listed on major exchanges and those participating in the private equity market. As a closed-end fund, BTX offers investors a way to access a diversified portfolio of growth-oriented companies, managed by experienced professionals within the BlackRock organization.
What Products and Services Does BTX Offer?
- Invests in equity securities of mid- and small-capitalization companies.
- Targets companies with above-average earnings growth potential.
- Focuses on innovative companies introducing new products or services.
- Aims to provide total return and income through current income, current gains, and long-term capital appreciation.
- Operates as a non-diversified, closed-end management investment company.
- Actively manages a portfolio of growth-oriented companies in the technology and private equity sectors.
How Does BTX Make Money?
- Generates income through dividends and interest from portfolio companies.
- Realizes capital gains through the sale of appreciated equity securities.
- Manages a closed-end fund structure, allowing for a stable pool of capital for investment.
- Leverages BlackRock's expertise in investment management and research to identify promising investment opportunities.
What Industry Does BTX Operate In?
BlackRock Technology and Private Equity Term Trust operates within the biotechnology industry, which is characterized by rapid innovation, high growth potential, and significant regulatory hurdles. The industry is driven by advancements in technology and increasing demand for new therapies and treatments. BTX's focus on mid- and small-cap companies allows it to tap into emerging trends and disruptive technologies that may be overlooked by larger investment firms. The competitive landscape includes other closed-end funds and investment firms specializing in growth-oriented healthcare companies. BTX differentiates itself through its emphasis on innovation and its access to BlackRock's extensive research and investment resources.
Who Are BTX's Key Customers?
- Institutional investors seeking exposure to growth-oriented companies.
- Retail investors looking for income and capital appreciation.
- Wealth management firms seeking diversified investment options for their clients.
- Pension funds and endowments seeking long-term growth opportunities.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a fund, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 56 snapshots
| 2026-08-23 | 44 |
| 2026-09-03 | 44 |
| 2026-09-14 | 44 |
| 2026-09-25 | 44 |
| 2026-10-09 | 44 |
| 2026-10-26 | 44 |
What changed?
The score has stayed at 44.
Over the same 31 days the stock moved -5.3%.
Key Financial Metrics
Return on equity for BlackRock Technology and Private Equity Term Trust stands at 0.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 83.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.13 means current liabilities exceed short-term assets, a liquidity point worth watching.
BTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on innovative growth companies.
- High dividend yield of 9.42%.
- Strong profit margin of 87.7%.
- Access to BlackRock's resources and expertise.
Bear Case
- Non-diversified investment approach.
- High P/E ratio of 2.32.
- Beta of 1.27 indicates higher volatility.
- Newly organized with no operating history.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · May 2026
BTX Latest News
No recent news available for BTX.
BTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BTX.
Price Targets
Wall Street price target analysis for BTX.
BTX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BTX; grades run from A+ (80-100) to F (below 30).
Leadership: John M. Perlowski
Unknown
Information about John M. Without additional data, it is impossible to provide details on his career history, education, or previous roles.
Track Record: Information about John M. Perlowski's track record is not available in the provided context. Without additional data, it is impossible to provide details on his key achievements, strategic decisions, or company milestones under his leadership.
BTX Healthcare Stock FAQ
What are the main risks for BTX?
The main risks for BlackRock Technology and Private Equity Term Trust (BTX) include market volatility, regulatory changes in the healthcare sector, and competition from other investment firms. As a non-diversified fund, BTX is more susceptible to fluctuations in the value of its holdings.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited source data.
- CEO information is incomplete.